Anifrolumab for Recalcitrant Cutaneous Lupus and Dermatomyositis

The presentation discusses the use of anifrolumab, a monoclonal antibody targeting the type 1 interferon receptor, for treating recalcitrant cutaneous lupus and dermatomyositis. A case study highlighted a patient with severe dyscoid lupus who had failed various previous treatments, including hydroxychloroquine and systemic steroids. Despite contraindications for thalidomide and lenalidomide due to her history of thrombosis, anifrolumab resulted in significant improvement of her skin condition, indicating its potential as an effective therapy. The speaker noted that over 20 additional patients were treated with rapid clinical improvement reported. Subsequent multi-center studies further demonstrated anifrolumab's effectiveness in both adult and adolescent populations with severe cutaneous lupus. Additionally, the speaker shared results from treating juvenile dermatomyositis with anifrolumab, showing promising skin improvement and even resolution of myositis symptoms in some cases. The therapeutic success of these anti-interferon therapies in challenging skin conditions has led to reconsideration of treatment algorithms, suggesting earlier intervention with anifrolumab to prevent irreversible skin damage. The findings emphasize the need for ongoing clinical trials for both anifrolumab and related therapies, as they show a strong potential in managing complex autoimmune skin diseases.